California Public Employees Retirement System Atara Biotherapeutics, Inc. Transaction History

California Public Employees Retirement System

$141 Billion
Q3 2024

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 13, 2021	SELL	$12.89 - $16.58 $1.84 Million - $2.37 Million	-142,706 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$14.0 - $20.72 $198,898 - $294,369	-14,207 Reduced 9.05%	142,706 $2.05 Million
Q4 2020 Feb 02, 2021	BUY	$12.67 - $26.23 $83,786 - $173,458	6,613 Added 4.4%	156,913 $3.08 Million
Q3 2020 Nov 05, 2020	BUY	$11.92 - $15.87 $406,472 - $541,167	34,100 Added 29.35%	150,300 $1.95 Million
Q2 2020 Aug 12, 2020	BUY	$7.53 - $14.93 $12,657 - $25,097	1,681 Added 1.47%	116,200 $1.69 Million
Q1 2020 May 12, 2020	BUY	$5.69 - $17.78 $44,951 - $140,462	7,900 Added 7.41%	114,519 $975,000
Q4 2019 Jan 27, 2020	BUY	$10.89 - $16.79 $536,593 - $827,310	49,274 Added 85.93%	106,619 $1.76 Million
Q3 2019 Oct 31, 2019	BUY	$12.03 - $19.94 $251,968 - $417,643	20,945 Added 57.54%	57,345 $810,000
Q2 2019 Aug 15, 2019	BUY	$19.05 - $41.04 $28,575 - $61,560	1,500 Added 4.3%	36,400 $732,000
Q1 2019 May 03, 2019	SELL	$28.4 - $41.74 $435,656 - $640,291	-15,340 Reduced 30.53%	34,900 $1.39 Million
Q4 2018 Feb 08, 2019	BUY	$30.9 - $42.97 $119,706 - $166,465	3,874 Added 8.36%	50,240 $1.75 Million
Q3 2018 Nov 13, 2018	SELL	$35.05 - $43.5 $33,753 - $41,890	-963 Reduced 2.03%	46,366 $1.92 Million
Q2 2018 Aug 15, 2018	SELL	$35.15 - $51.45 $321,517 - $470,613	-9,147 Reduced 16.2%	47,329 $1.74 Million
Q1 2018 May 11, 2018	BUY	$18.0 - $48.35 $1.02 Million - $2.73 Million	56,476 New	56,476 $2.2 Million

Others Institutions Holding ATRA

# of Institutions

Shares Held

2.89M

Call Options Held

Put Options Held

View Full List

About Atara Biotherapeutics, Inc.

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $1.08B
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

More about ATRA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of California Public Employees Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on California Public Employees Retirement System with notifications on news.

Account